William Schary

1.3k total citations
26 papers, 623 citations indexed

About

William Schary is a scholar working on Genetics, Pharmacology and Pathology and Forensic Medicine. According to data from OpenAlex, William Schary has authored 26 papers receiving a total of 623 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Pharmacology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in William Schary's work include Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (6 papers) and Pharmacogenetics and Drug Metabolism (5 papers). William Schary is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (6 papers) and Pharmacogenetics and Drug Metabolism (5 papers). William Schary collaborates with scholars based in United States, United Kingdom and Germany. William Schary's co-authors include Malcolm Rowland, Richard J. Lewis, Kenneth K. Chan, M. Orme, William Trager, Arthur B. Straughn, AM Breckenridge, Michele C. Meyer, Ming Lo and Man‐Wai Lo and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

William Schary

25 papers receiving 572 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William Schary United States 10 220 117 113 89 71 26 623
R. G. Cooper United Kingdom 8 172 0.8× 141 1.2× 124 1.1× 78 0.9× 38 0.5× 10 744
DG Waller United Kingdom 17 241 1.1× 137 1.2× 79 0.7× 229 2.6× 38 0.5× 28 920
J. P. Cano France 16 260 1.2× 123 1.1× 199 1.8× 319 3.6× 109 1.5× 57 1.0k
Donald W. Everett United States 11 177 0.8× 55 0.5× 162 1.4× 122 1.4× 76 1.1× 12 753
J.P. Desager Belgium 18 173 0.8× 121 1.0× 130 1.2× 122 1.4× 19 0.3× 68 1.1k
F Perlı́k Czechia 17 165 0.8× 148 1.3× 126 1.1× 109 1.2× 21 0.3× 71 791
Pil-Whan Park South Korea 15 90 0.4× 87 0.7× 120 1.1× 134 1.5× 19 0.3× 45 613
Achiel Van Peer Belgium 19 319 1.4× 215 1.8× 208 1.8× 202 2.3× 68 1.0× 43 1.2k
L. Skovsted Denmark 24 304 1.4× 161 1.4× 153 1.4× 227 2.6× 48 0.7× 57 1.6k
George D. Olsen United States 17 96 0.4× 152 1.3× 137 1.2× 62 0.7× 104 1.5× 41 824

Countries citing papers authored by William Schary

Since Specialization
Citations

This map shows the geographic impact of William Schary's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Schary with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Schary more than expected).

Fields of papers citing papers by William Schary

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Schary. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Schary. The network helps show where William Schary may publish in the future.

Co-authorship network of co-authors of William Schary

This figure shows the co-authorship network connecting the top 25 collaborators of William Schary. A scholar is included among the top collaborators of William Schary based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Schary. William Schary is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McNeill, Ann, et al.. (2023). Prognosis of older adults with chronic lymphocytic leukemia: A Surveillance, Epidemiology, and End Results-Medicare cohort study. Journal of Geriatric Oncology. 14(8). 101602–101602. 6 indexed citations
2.
Lewis, Lionel D., William Schary, Siddhartha De, et al.. (2022). 603 A randomized, placebo-controlled, first in human phase I single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy male volunteers of the immunostimulant 7HP349. Regular and Young Investigator Award Abstracts. A632–A632. 1 indexed citations
3.
Stilgenbauer, Stephan, Franck Morschhauser, Clemens‐Martin Wendtner, et al.. (2020). Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440). Haematologica. 106(11). 2834–2844. 3 indexed citations
4.
5.
Fraser, Graeme, Brian Leber, Reinhard Marks, et al.. (2019). PS1161 EFFICACY AND SAFETY OF IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS PREVIOUSLY TREATED WITH VENETOCLAX IN THE MURANO STUDY. HemaSphere. 3(S1). 527–527. 2 indexed citations
6.
7.
8.
Benedek, Irma H., et al.. (1992). Effect of Moricizine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers. The Journal of Clinical Pharmacology. 32(6). 558–563. 8 indexed citations
9.
Pieniaszek, Henry J., et al.. (1991). Influence of Food on the Oral Absorption and Bioavailability of Moricizine. The Journal of Clinical Pharmacology. 31(9). 792–795. 3 indexed citations
10.
Lo, Man‐Wai, et al.. (1987). The Disposition and Bioavailability of Intravenous and Oral Nalbuphine in Healthy Volunteers. The Journal of Clinical Pharmacology. 27(11). 866–873. 32 indexed citations
11.
Lo, Man-Wai, et al.. (1987). The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. European Journal of Clinical Pharmacology. 33(3). 297–301. 21 indexed citations
12.
Howrie, Denise L., Henry J. Pieniaszek, Richard N. Fogoros, et al.. (1987). Disposition of moracizine (ethmozine) in healthy subjects after oral administration of radiolabelled drug. European Journal of Clinical Pharmacology. 32(6). 607–610. 13 indexed citations
13.
Zetin, Mark, et al.. (1985). Bioavailability of oral and intramuscular molindone hydrochloride in schizophrenic patients.. PubMed. 7(2). 169–75. 4 indexed citations
14.
Honigberg, I.L., James T. Stewart, Jeffrey A. Kotzan, et al.. (1984). In vitro and in vivo bioequivalence of commerical prednisone tablets. Biopharmaceutics & Drug Disposition. 5(4). 335–344. 9 indexed citations
15.
Meyer, Marvin C., et al.. (1984). Absorption of Phenobarbital from Tablets and Elixir. Journal of Pharmaceutical Sciences. 73(4). 485–488. 7 indexed citations
16.
Meyer, Michele C., et al.. (1984). Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.. PubMed. 45(9 Pt 2). 15–9. 145 indexed citations
17.
Schary, William & Malcolm Rowland. (1983). Protein binding and hepatic clearance: Studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver preparation. Journal of Pharmacokinetics and Biopharmaceutics. 11(3). 225–243. 44 indexed citations
18.
Schary, William, Leon Aarons, & Malcolm Rowland. (1978). Representation and interpretation of drug displacement interactions. Biochemical Pharmacology. 27(1). 139–144. 7 indexed citations
19.
Aarons, Leon, William Schary, & Malcolm Rowland. (1977). On Representation and Interpretation of Drug Displacement Interactions. Journal of Pharmacy and Pharmacology. 29(Supplement_1). 2P–2P. 1 indexed citations
20.
Schary, William, Richard J. Lewis, & Malcolm Rowland. (1975). Warfarin-phenylbutazone interaction in man: a long term multiple dose study.. PubMed. 10(4). 663–72. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. G. Cooper Breakdown of academic impact, for papers by DG Waller Breakdown of academic impact, for papers by J. P. Cano Breakdown of academic impact, for papers by Donald W. Everett Breakdown of academic impact, for papers by J.P. Desager Breakdown of academic impact, for papers by F Perlı́k Breakdown of academic impact, for papers by Pil-Whan Park Breakdown of academic impact, for papers by Achiel Van Peer Breakdown of academic impact, for papers by L. Skovsted Breakdown of academic impact, for papers by George D. Olsen
Rankless by CCL
2026